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Summary
Enterococcus faecium strain 9631355 was isolated
from animal sources on the basis of its resistance to
the growth promotant avilamycin. The strain also
exhibited high-level resistance to evernimicin, a drug
undergoing evaluation as a therapeutic agent in
humans. Ribosomes from strain 9631355 exhibited a
dramatic reduction in evernimicin binding, shown by
both cell-free translation assays and direct-binding
assays. The resistance determinant was cloned from
strain 9631355; sequence alignments suggested it
was a methyltransferase and therefore it was desig-
nated emtA for evernimicin methyltransferase. Ever-
nimicin resistance was transmissible and emtA was
localized to a plasmid-borne insertion element.
Puriﬁed EmtA methylated 50S subunits from an
evernimicin-sensitive strain 30-fold more efﬁciently
than those from a resistant strain. Reverse transcrip-
tion identiﬁed a pause site that was unique to the 23S
rRNA extracted from resistant ribosomes. The pause
corresponded to methylation of residue G2470
(Escherichia coli numbering). RNA footprinting
revealed that G2470 is located within the ever-
nimicin-binding site on the ribosome, thus providing
an explanation for the reduced binding of the drug to
methylated ribosomes.
Introduction
There is growing alarm regarding the proliﬁc use of
antibiotics and the concomitant spread of drug resistance
among human clinical strains, particularly among the
enterococci (Huycke et al., 1998). The localization of
resistance determinants to plasmids and conjugative
transposons has facilitated their dissemination, resulting
in both intraspecies and intergeneric gene transfer (Nobel
et al., 1992). Extensive use of antibiotics, both therapeuti-
cally and as growth promotants in animal feed, has
resulted in a similar problem in animals (Aarestrup et al.,
1998a; Van den Bogaard and Stobberingh, 1999).
Particular concern arises when animal isolates exhibit
cross-resistance to antibiotics used to treat humans
(Aarestrup, 1998; Aarestrup et al., 1998b). Such strains
could transfer antibiotic resistance to human clinical
strains. This route has been demonstrated both in the
laboratory (Khan et al., 2000) and in the human gut
(Shoemaker et al., 2001). Direct colonization of humans by
resistant animal isolates would provide a more direct
route; current data suggests that this occurs rarely (Van
den Bogaard and Stobberingh, 1999).
Evernimicin, a novel oligosaccharide antibiotic (Ganguly
et al., 1989), is active against a broad range of Gram-
positive pathogenic bacteria (Jones and Barret, 1995).
The drug binds a single high-afﬁnity site on the 50S
ribosomal subunit (McNicholas et al., 2000) and may
inhibit protein synthesis by interfering with binding of
initiation factor 2 (Belova et al., 2001). Consistent with its
binding site, evernimicin resistance was caused by
mutations in both rplP (encodes the 50S associated
protein L16) in Streptococcus pneumoniae and Staphylo-
coccus aureus (Adrian et al., 2000a; McNicholas et al.,
2001) and in domain V of the 23S rRNA in S. pneumoniae
and Halobacterium halobium (Adrian et al. 2000b;
Belova et al., 2001). One source of rplP mutants is
Enterococcal isolates from animals given the growth
promotant avilamycin, a structural analogue of evernimicin
(Aarestrup and Jensen, 2000; this study). These mutants
also exhibited limited cross-resistance to evernimicin
(Aarestrup, 1998). In this study, we characterize an
enterococcal isolate from animals, which encodes a
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Q 2001 Blackwell Science Ltdmethyltransferase that confers high-level evernimicin
resistance through methylation of 23S rRNA.
Results
Identiﬁcation of an E. faecium strain encoding
transmissible high-level evernimicin resistance
Twenty avilamycin-resistant (minimum inhibitory concen-
tration (MIC).64mgml
21) enterococcal strains (eleven
Enterococcus faecalis and nine E. faecium) were obtained
from the Danish Integrated Antimicrobial Resistance
Monitoring and Research Programme (Aarestrup et al.,
1998a). Nineteen strains exhibited low-level cross-
resistance to evernimicin (MIC,12mgml
21) and all had
single point mutations in rplP. A similar result was reported
recently (Aarestrup and Jensen, 2000). E. faecium strain
9631355 exhibited an evernimicin MIC.256mgml
21 and
had no mutations in either rplP or the 23S rDNA. The
evernimicin-resistant phenotype was transferable; using
the recipient strain 27270RF (evernimicin MIC
0.5mgml
21), we obtained evernimicin-resistant transcon-
jugants (MIC . 256mgml
21) at an average frequency of
116
26 per recipient colony-forming unit in liquid media.
No other drug-resistance markers appeared to be co-
transferred. The transconjugants generated above trans-
ferred evernimicin resistance to strain 27270S at the
same frequency as strain 9631355 (data not shown).
There were no differences in growth rates between
isogenic recipient (27270RF) and transconjugant
(27270TC1) strains (27270TC1 was grown in both the
presence and absence of evernimicin).
High-level evernimicin resistance is associated with an
alteration in the ribosomes
We measured the susceptibility of ribosomes, isolated
from strains exhibiting varying levels of evernimicin
resistance, to inhibition by evernimicin in a cell-free
translation assay. The S100 extract, which provides the
ancillary factors required for protein synthesis, was
isolated from strain 27270 (evernimicin MIC 0.5mgml
21).
Ribosomes were isolated from strain 27270, strain
9508106 (which carries a rplP mutation (MIC 4mgml
21))
and strain 9631355 (MIC.256mgml
21). In the absence
of drug, the ribosomes all synthesized similar amounts of
labelled protein (data not shown). Addition of evernimicin
inhibited ribosomes from strain 27270 in a dose-
dependent manner; 95% inhibition occurred at approxi-
mately 0.3mgml
21 (195nM, Fig.1). To achieve 95%
inhibition of ribosomes from strain 9508106 (the rplP
mutant) required eightfold more evernimicin. Ribosomes
from strain 9631355 showed no inhibition at 160mgml
21
(100mM). The above susceptibilities were mirrored by the
capacity of the ribosomes to bind [
14C]-evernimicin
(Fig.2). Similar to previous data (McNicholas et al.,
2000), wild-type ribosomes exhibited a Kd of 200nM and a
1:1 stoichiometry of bound drug to ribosomes. Ribosomes
from strain 9508106 exhibited a Kd of 400nM. Under
the conditions used here, we did not detect binding of
[
14C]-evernimicin to ribosomes from strain 9631355. We
repeated the binding assay using ribosomes from isogenic
recipient (27270RF) and transconjugant (27270TC1)
strains. Ribosomes from strain 27270RF exhibited a Kd
of 100nM. We were unable to detect binding to ribosomes
from strain 27270TC1 (data not shown). In contrast, both
sets of ribosomes bound [
14C]-erythromycin with a Kd of
50nM (data not shown) that is similar to a previous
determination (Pestka, 1976).
Cloning and sequence analysis of the
evernimicin-resistance determinant, emtA
A plasmid library, constructed from total cellular DNA
Fig.1. Effect of evernimicin on cell-free translation reactions.
Reactions were performed using an S100 extract isolated from the
evernimicin-sensitive E. faecium strain 27270 and ribosomes isolated
from the following E. faecium strains; 27270 (evernimicin MIC
0.5mgml
21, V); 9508106 (a rplP mutant, MIC 4mgml
21, O)a n d
9631355 (MIC.256mgml
21, B). For each set of ribosomes,
incorporation of [
3H]-lysine into hot TCA-precipitable material is
expressed as a percentage of the control (no antibiotic) reaction.
Fig.2. Non-linear regression analysis of [
14C]-evernimicin binding to
70S ribosomes. Binding was performed with ribosomes isolated from
the following E. faecium strains: 27270 (evernimicin MIC 0.5mgml
21,
V); 9508106 (MIC 4mgml
21; O) and 9631355 (MIC.256mgml
21,
B). The amount of bound [
14C]-evernimicin was calculated from a
standard curve.
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high-level evernimicin resistance. We identiﬁed two
identical clones; the 3837bp insert in pPAM19 had the
coding potential for two full-length open reading frames
(ORFs) and two truncated ORFs (Fig.3). Deletion of
the SphI fragment from pPAM19 did not impair ever-
nimicin resistance, implying that the ORF labelled emtA
encoded the resistance determinant (Fig.3). Sequence
alignments using PSI-BLAST (Altschul et al., 1997)
produced a number of weak matches to EmtA; the best
was a hypothetical protein (accession number BAA79525)
from Aeropyrum pernix whose GenBank entry indicated
that it contained an ‘adenine-speciﬁc DNA methylase
signature’. Similarly, the top hits, using IMPALA (Schaffer
et al., 1999) and the threading algorithm PROFIT (Flockner
et al., 1997), were the UbiE methyltransferase family of
proteins and a cobalt-precorrin-4 methyltransferase
respectively. Therefore we labelled the resistance ORF
emtA for evernimicin methyltransferase.
EmtA is located on a plasmid-borne transposable element
emtA and a second full-length ORF, labelled tnpA, are
ﬂanked by imperfect inverted repeats (24bp at the 50-end
and 25bp at the 30-end with four mismatched bases) that
are themselves ﬂanked by 8bp AT-rich direct repeats
(Fig.3). TnpA exhibited 37% identity and 58% similarity
with TnpA from ISPs1 (Bolognese et al., 1999). Based on
these features, the transposon appears to belong to the
ISL3 family (Mahillon and Chandler, 1998). The truncated
ORF at the 30-end of the insert exhibited 96% homology
to the terminal half of zeta, a gene present on numerous
Gram-positive plasmids including pDB101 from S.
pyogenes (Ceglowski and Alonso, 1994). Immediately
downstream of zeta, on pDB101, is a cluster of ORFs
including epsilon, delta and gamma. To determine whether
emtA is linked to the same ORFs in 27270TC1, we
performed a polymerase chain reaction (PCR) analysis
using chromosomal DNA and an emtA-speciﬁc primer in
combination with primers speciﬁc to the 50-ends of ORFs
zeta, epsilon, delta and gamma. In all cases, we obtained
PCR products of a size consistent with the gene
arrangement seen in pDB101 (data not shown). By
sequencing the region upstream of emtA in 27270TC1, we
identiﬁed an ORF with 80% homology to mob, a gene
located on a Lactococcus lactis plasmid (Wang and
Macrina, 1995). Plasmid analysis revealed that strain
9631355 contained multiple plasmids; 27270RF was
plasmid-free and 27270TC1 harboured a single plasmid
(estimated using restriction analysis to be 40kb) similar
in size to a plasmid in strain 9631355 (data not shown).
Southern blotting localized emtA to the large plasmid in
27270TC1 (data not shown) and treatment of strains
9631355 and 27270TC1 with novobiocin, an agent known
to interfere with plasmid replication, cured evernimicin
resistance (loss of emtA was conﬁrmed by PCR analysis)
at frequencies of 2% and 15% respectively.
EmtA preferentially methylates the 50S subunit of
sensitive ribosomes
Sequences encoding a hexa-histidine tag were appended
to the 30-end of emtA and the modiﬁed gene was
cloned into pET29a generating pPAM25. In HS294, an
evernimicin-sensitive Escherichia coli strain (MIC
4mgml
21), pPAM25 conferred IPTG-dependent, high-
level evernimicin resistance. Growth of BL21(pPAM25) in
Fig.3. Diagrammatic representation of the open reading frames (ORFs) present in the cloned fragment conferring high-level evernimicin resistance.
The size and orientation of the various ORFs are shown as the SphI restriction sites used to generate pPAM21. Hatched lines represent vector
sequences. Shown below is the DNA sequence of the inverted repeats and the ﬂanking direct repeats; mismatches in the inverted repeats are
underlined.
Fig.4. Methylation of 70S ribosomes. Ribosomes, from isogenic
recipient (evernimicin MIC 0.5mgml
21; 27270RF, V)a n d
transconjugant (evernimicin MIC.256mgml
21; 27270TC1, B)
strains were incubated with varying amounts of puriﬁed EmtA and
[methyl-
3H]-S-adenosylmethionine. After 45min at 378C, the reactions
were stopped by addition of a large excess of unlabelled SAM and
unincorporated label removed by passage through a size exclusion
column.
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overexpression of EmtA. Nevertheless, EmtA was puriﬁed
from cell lysates; the protein was 90% pure and migrated
at the predicted molecular weight (data not shown).
Methylation of intact ribosomes from isogenic donor and
transconjugant strains, using puriﬁed EmtA and
[methyl-
3H]-S-adenosylmethionine ([methyl-
3H]-SAM),
resulted in less than twofold discrimination between
evernimicin-resistant and -sensitive strain ribosomes
(data not shown). Lowering the magnesium content of
the reaction buffer from 10 to 1mM increased overall
labelling fourfold and also resulted in a modest (fourfold)
discrimination between sensitive and resistant ribosomes
(Fig.4). Label incorporation was linear up to 30min, after
which no further increases were observed, and was
abolished by either heat denaturation of EmtA (2min at
1008C) or by increasing the proportion of unlabelled SAM
in the reaction 100-fold (data not shown). Addition of
evernimicin also inhibited methylation in a dose-depen-
dent manner; maximal inhibition, 50% of the control value,
occurred at an evernimicin concentration of 250nM.
Attempts to methylate rRNA extracted from evernimicin-
sensitive ribosomes were unsuccessful. To identify which
subunit was being methylated, we methylated 70S
ribosomes and then resolved the individual ribosomal
subunits on sucrose gradients. In reactions utilizing
evernimicin-sensitive ribosomes, the majority of the
radiolabel was associated with the 50S subunit and with
aspeciesthatmigratedslightlyslowerthanthe50Ssubunit
(data not shown). Again, evernimicin-resistant ribosomes
were labelled fourfold less efﬁciently and the label was
associated primarily with the 30S subunit (data not
shown). We repeated the assay using puriﬁed ribosomal
subunits (Fig.5). Comparison of the amount of label
associated with fraction #7, which corresponds to the
centre of the 50S peak, revealed that subunits from a
sensitive strain were labelled 30-fold more efﬁciently than
those from a resistant strain. The 30S subunits from both
resistant and sensitive strains were not methylated (data
not shown). Approximately 1% of the evernimicin-sensitive
50S subunits were methylated and addition of increased
amounts of EmtA to the reaction did not increase label
incorporation signiﬁcantly (data not shown). To determine
whether in vitro methylation blocked evernimicin binding,
we methylated 50S subunits using unlabelled SAM and
then added either [
14C]-evernimicin or [
14C]-erythromycin
at four times the measured Kd. Methylation had no
effect on the binding of either drug (data not shown).
Finally, to test the effect of magnesium on methylation,
we methylated 50S subunits in buffer containing either 1
or 10mM of magnesium; methylation was reduced
approximately fourfold at the higher concentration.
The target site for methylation by EmtA overlaps the
evernimicin binding site
To identify the target site for EmtA methylation, we
performed primer extension on 23S rRNA extracted
Fig.5. Fractionation of in vitro methylated 50S ribosomal subunits.
50S subunits from recipient strain 27270RF (evernimicin MIC
0.5mgml
21) and transconjugant strain 27270TC1 (evernimicin
MIC.256mgml
21) were incubated with puriﬁed EmtA and
[methyl-
3H]-S-adenosylmethionine as described in Experimental
procedures. The reactions were resolved on sucrose gradients and for
each fraction the optical density at 260nm (27270RF, B and
27270TC1, V) and radioactivity (27270RF, O and 27270TC1, X) were
determined.
Fig.6. Identiﬁcation of the methylation site. 23S rRNA was extracted
from ribosomes isolated from isogenic recipient (evernimicin MIC
0.5mgml
21), 27270RF (1) and transconjugant (evernimicin
MIC.256mgml
21), 27270TC1 (2) strains. Both batches of rRNA
were reverse transcribed from primer #3 (see Experimental
procedures) and the products resolved on denaturing polyacrylamide
gels. A sequencing ladder, utilizing the same primer as above and 23S
rRNA from strain 27270RF, was run on the same gel. An arrow
indicates the pause site.
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-resistant strains. We identiﬁed a single pause site, unique
to rRNA isolated from resistant ribosomes (Fig.6), that
corresponded to methylation of guanine 2470 in helix 89
(E. coli numbering, Fig.7). We used two additional primers
that annealed to different sites to conﬁrm this data (data
not shown). Evernimicin was footprinted previously to
helices 89 and 91 in ribosomes from E. coli and
H. halobium (Belova et al., 2001). We repeated this
analysis using E. faecium ribosomes; here we scanned
nucleotides 2400–2650 only. When bound to sensitive
ribosomes, the drug protected a number of adenine
residues ﬂanking the proposed methylation site (Fig.6). In
contrast, we saw no protection when using evernimicin-
resistant ribosomes (data not shown).
Discussion
Prior to this study, evernimicin resistance had been
associated solely with mutations in genes encoding
ribosomal components, speciﬁcally rplP and the 23S
rDNA. In this study, we characterized an E. faecium strain
capable of mediating transfer of high-level evernimicin
resistance. Probable resistance mechanisms included
drug efﬂux, drug modiﬁcation and ribosome modiﬁcation.
To differentiate between these possibilities, we examined
the interaction of evernimicin with ribosomes isolated from
the resistant strain. The ribosomes exhibited a dramatic
reduction in evernimicin binding and were refractory to
inhibition by evernimicin in cell-free translation assays,
suggesting that they had been modiﬁed in some manner.
We cloned the gene responsible and demonstrated that it
was functional in E. coli, suggesting the target site for
modiﬁcation is conserved between both Gram-positive
and -negative organisms. Sequence analysis indicated
that the resistance gene encoded a protein with a SAM-
binding site. Therefore it was designated emtA for
evernimicin methyltransferase.
Initial attempts to demonstrate methyltransferase
activity, using puriﬁed EmtA, yielded low levels of
methylation and no discrimination between ribosomes
from sensitive and resistant strains. Reducing the
magnesium content of the reaction buffer increased
overall levels of methylation and resulted in sensitive
ribosomes being methylated between three- and fourfold
more efﬁciently than resistant ribosomes. This discrimi-
nation was increased to 30-fold when the substrate for
methylation was puriﬁed 50S subunits. Thus, it would
appear that the in vitro methylation reaction accurately
mimics in vivo methylation in terms of site speciﬁcity. The
requirement for low magnesium may either be a physical
characteristic of the enzyme or may stem from the fact that
70S ribosomes dissociate under low magnesium con-
ditions that, in turn, may unmask a previously hidden site
of methylation. Methylation reactions using puriﬁed 50S
subunits exhibited a similar magnesium dependency
suggesting that the effect is a characteristic of the enzyme
(see below).
Only 1% of the puriﬁed 50S subunits were methylated by
EmtA in vitro and therefore it was not surprising that
methylation did not block evernimicin binding. One
explanation for the low levels of methylation is that EmtA
is onlypartially functional. This may be a result of his-tagging
the enzyme or due to damage sustained during puriﬁcation.
However, this seems unlikely as adding more EmtA to a
reaction didnot result in asigniﬁcantincrease in methylation.
Alternatively, the intact 50S subunit may not be the preferred
substrate for EmtA. In the sucrose fractionation experiments
using both intact ribosomes and puriﬁed subunits, the
labelled SAM was associated with both the 50S subunit and
with a species that migrated slightly more slowly. It is
conceivable that this species, which may represent a 50S
precursor particle, is the preferred substrate for EmtA and,
as such, may be present in low amounts in our ribosome
preparations. Preliminary data suggested that the ErmC
methylase recognizes and interacts with a similar precursor
particle (Champney, 2001). Furthermore, it has been
postulated that evernimicin interacts with a 50S assembly
intermediate and in some manner blocks ribosome
assembly (Champney and Tober, 2000).
A single pause site in the 23S rRNA, that was unique to
rRNA isolated from resistant ribosomes, was identiﬁed by
primer extension. The pause site corresponded to
methylation of G2470. A number of lines of evidence
strongly suggest that the evernimicin binding site overlaps
Fig.7. Location of the sites of EmtA methylation and evernimicin
binding. The peptidyl transferase loop (domain V) from E. faecium
27270 is diagrammatically represented. Residues protected by
evernimicin from modiﬁcation by dimethyl sulphate are boxed and the
residue methylated by EmtA is circled.
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isolated from E. coli, H. halobium (Belova et al., 2001) and
E. faecium (this study) identiﬁed rRNA contact points in the
same hairpin. Similarly, mutations that confer evernimicin
resistance in S. pneumoniae and H. halobium were also
mapped to this hairpin; the nearest nucleotide substitution
was located at residue 2471 (Adrian et al., 2000b; Belova
et al., 2001). Finally, addition of evernimicin to the
methylation reactions inhibited methylation of ribosomes
in a dose-dependent manner.
The origin of emtA is intriguing; EmtA had no signiﬁcant
homology with the Erm family of methylases and the best
match from public databases was an archeal protein with a
putative methyltransferase function. Recently, a large
gene cluster encoding enzymes required for evernimicin
biosynthesis in Micromonospora carbonacea was
sequenced (unpublished data). EmtA exhibited 25%
identity and 42% similarity with EvrH, an ORF of unknown
function from this cluster. Finally, two rRNA methyltrans-
ferases, AviRa and AviRb, that conferred resistance to
avilamycin, were recently cloned from the avilamycin
producer Streptomyces viridochromogenes (Weitnauer
et al., 2001). AviRa had no homology to proteins in the
data bases and AviRb resembled the SpoU family of
methyltransferases. However, despite the strong struc-
tural similarity between avilamycin and evernimicin,
neither protein exhibited signiﬁcant homology to either
EmtA or EvrH.
Experimental procedures
Bacterial strains and growth conditions
Strains and plasmids are listed in Table1. Evernimicin was
isolated at Schering-Plough Research Institute and solubil-
ized as the clinical formulation at 16mgml
21. Avilamycin was
a gift from Elanco Animal Health; all other antibiotics were
purchased from Sigma Chemical Co. MIC determinations
were performed using trypticsoy broth, antibiotics were added
in doubling dilutions and the MIC recorded as the lowest
antibiotic concentration that inhibited growth after 16h at
378C.
Genetic techniques
Spontaneous mutants of E. faecium strain ATCC 27270,
resistant to either streptomycin (27270S) or to both fusidic
acid and rifampicin (27270RF), were selected on the
appropriate plates. For liquid matings, equal volumes of
fresh overnight cultures (grown in brain–heart infusion
medium) of donor and recipient strains were mixed, incubated
at 378C for 4h and plated on selective media. Arbitrarily
primed polymerase chain reaction (PCR), using p38 (50-
CGGTGGCGAA-30)a n dB O X( 5 0-CTACGGCAAGGC
GACGCTGACG-30), was used to conﬁrm the identity of
transconjugants. Novobiocin curing of plasmids was per-
formed as described (McHugh and Schwartz, 1977).
Manipulation and sequencing of DNA
DNA manipulations were carried out according to standard
procedures (Sambrook et al., 1989). DNA sequencing was
performed using an ABI Prism Big Dye Terminator Cycle
Sequencing Kit and the products resolved using a 310
Genetic Analyser. Transformation (Shepard and Gilmore,
1995) and extraction of plasmid DNA from E. faecium were
performed as described (Woodford et al., 1993).
Cloning of emtA
Total DNA was extracted from E. faecium 27270TC1 by
incubating cells in 0.5% of SDS/0.1mgml
21 proteinase K for
Table1. Bacterial strains and plasmids used in this study.
Strain or plasmid Origin Relevant genotype or phenotype
a Source or reference
E. faecium
ATCC 27270 Wild-type strain Laboratory stock
9508106 Animal isolate Av
r Ev
r Aarestrup et al. (1998a)
9631355 Animal isolate Av
r Ev
r Aarestrup et al. (1998a)
27270RF ATCC 27270 Rif
r Fus
r This study
27270S ATCC 27270 Str
r This study
27270TC1 Conjugation Rif
r Fus
r Ev
r This study
(963135527270RF)
E. coli strains
XL Blue 1 recA1 Laboratory stock
BL21 (lDE3) l lysogen carrying T7 polymerase Laboratory stock
HS294 lacZ::T7 polymerase, highly drug-susceptible strain Laboratory stock
Plasmids
pLI51 Shuttle vector Ap
r Cm
r Lee et al. (1987)
pPAM19 pLI51 Ev
r Ap
r Cm
r This study
pPAM21 pPAM19 Deletion of the SphI fragment Ev
r Ap
r Cm
r This study
pET29a T7 based over expression plasmid Kan
r Novagen
pPAM25 pET29a emtA with 6 histidine codons at 30-end Kan
r Ev
r This study
a. Ap
r, ampicillin-resistant; Av
r, avilamycin-resistant; Ev
r, evernimicin-resistant; Cm
r, chloramphenicol-resistant; Fus
r, fusidic acid-resistant; Kan
r,
kanamycin-resistant; Str
r, streptomycin-resistant.
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was precipitated with ethanol. Sau3A fragments (size range
of 3–5kb) were ligated into the BamH1 site of pLI51. The
library was ampliﬁed via passage through E. coli XL1-Blue.
Twofold coverage of the insert in pPAM19 was performed by
the Midland Certiﬁed Reagent Co. (GenBank accession
number AF403298).
Ribosome isolation and cell free translation reactions
Cells were lysed by passage through a microﬂuidizer and
ribosomes puriﬁed as described previously (Staehlin and
Marglott, 1971). Ribosomes and S100 extracts were
resuspended and dialysed, respectively, against B3 (10mM
of MgCl2, 20mM of Tris (pH7.8), 30mM of NH4Cl, 0.1mM of
EDTA and 6mM of b-mercaptoethanol). Ribosomal subunits
were obtained by fractionating ribosomes on 10–30%
sucrose gradients formed in B4 (B3 with 1mM of MgCl2 and
100mM of NH4Cl), subunit-containing fractions were
washed and concentrated using Microcon 30 ﬁlter devices
(Amicon). Cell free translation reactions using a polyA
template and [
3H]-lysine (speciﬁc activity 89Cimmol
21,
NEN) were performed as described (Mahmood et al., 1991)
and labelled proteins quantiﬁed by liquid scintillation counting
(McNicholas et al., 2000).
Binding assays
Binding reactions using [
14C]-evernimicin (speciﬁc activity
8mCimmol
21, Hesk et al., 1999) and [
14C]-erythromycin
(speciﬁc activity 55mCimmol
21, NEN) were performed as
described previously (McNicholas et al., 2000).
Puriﬁcation of EmtA
emtA was PCR ampliﬁed with the following primers to append
six histidine codons to the 30-end of the gene (50-CA
TATGACTCTTTATTTTGCGAGCG-30 and 50-GGGATCCTT
AGTGGTGGTGGTGGTGGTGCTTCCTTTTAAGTCCATC
T-30) and cloned into pET29a-generating pPAM25. EmtA was
puriﬁed from BL21(pPAM25) as follows: after resuspension in
lysis buffer (50mM of Na2HPO4 (pH8.0), 300mM of NaCl,
10mM of imidazole, 0.1% of b-mercaptoethanol, 10mgml
21
of lysozyme, 0.1M of PMSF, 0.1% of Triton X-100 and 10% of
glycerol), cells were disrupted in a microﬂuidizer. Cleared
lysates, obtained by centrifugation at 14000 g for 15min,
were incubated with Qiagen’s Ni-NTA slurry. After washing
and elution (according to the manufacturer’s protocol,
Qiagen), EmtA was dialysed against 50mM of Tris-HCl
(pH7.4), 40mM of KCl, 4mM of MgCl2, 10mM of DTT and
10% of glycerol.
In vitro methylation assays
Methylase reactions (50ml) were performed in buffer C
(50mM of Tris-HCl [pH7.4], 40mM of KCl, 10mM DTT and
either 10 or 1mM of MgCl2) containing 20mM of SAM, 0.5mM
of methyl [
3H]-SAM (speciﬁc activity 85Cimmol
21, NEN), 5U
of RNasin (Promega) and 12 pmoles of either 70S ribosomes
or rRNA (phenol extracted from 70S ribosomes). Reactions
were incubated for 45min at 378C and then chased for 15min
with 200mM of SAM. Labelled ribosomes were separated
from unincorporated label by centrifugation through size
exclusion columns (McNicholas et al., 2000) or by fraction-
ation on 10–30% sucrose gradients.
Primer extension and footprinting assays
Primer extension, using primers designed to amplify the entire
23S rRNA in 150bp increments, was performed as described
by Stern et al. (1988). Footprinting of evernimicin, bound to
ribosomes using dimethyl sulphate, was performed as
described by Merryman and Noller (1988) using primers
#1–3 (50-CGGCAGATAGGGACCGA-3’, 50-CAGCCCCAG
GATG-3’ and 50-CAGCCCCAGGATG-3’).
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